Abstract
Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients with liver tumors was initiated. By November 2001, enrollment had been completed in a second phase II study of refractory non-small-cell lung cancer (NSCLC). In June 2003, Titan began enrollment for a phase IIb trial of AN-9 in combination with docetaxel in patients with NSCLC.
MeSH terms
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Butyrates / adverse effects
-
Butyrates / metabolism
-
Butyrates / pharmacokinetics
-
Butyrates / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / metabolism
-
Drugs, Investigational / pharmacokinetics
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Neoplasms / drug therapy
Substances
-
Antineoplastic Agents
-
Butyrates
-
Drugs, Investigational
-
pivalyloxymethyl butyrate